Results 101 to 110 of about 4,521 (193)

Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients [PDF]

Objective: To assess the efficacy and safety of Filgotinib for the management of cutaneous, visceral and articular involvement in pat ients affected by systemic sclerosis.
A Spinella, AF Guerra, F Lumetti, G Amati, G Sandri, Giuggioli D, M De Pinto, O Secchi, P Macripò   +8 more
core  

Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA). [PDF]

Rheumatol Ther
Pongratz G, Alten R, Witte T, Pausch C, Reinhold R, Pittrow D, Burmester GR.   +6 more
europepmc   +1 more source

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. [PDF]

PLoS One
Shi Y, Guan S, Wang S, Li M, Yu Y, Liu J, Yang W, Wang Z.   +7 more
europepmc   +1 more source

Revisiting Janus kinases as molecular drug targets for rheumatic diseases. [PDF]

Front Med (Lausanne)
Kwon S.
europepmc   +1 more source

Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. [PDF]

World J Gastrointest Pharmacol Ther
Malakar S, Giri S, Jena A, Nath P.
europepmc   +1 more source

Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohort. [PDF]

Rheumatol Adv Pract
Nathan J, Farisogullari B, Jones N, Ayoub M, Brown J, Levy S, Brader J, Ersoy A, Israni B, Lloyd M, Latheef A, Hill D, Taylor A, Arachchige D, Chitsu H, Linklater H, Lather K, Gompels L, Elfar E, Malaiya R, Machado PM, Kiely PDW.   +21 more
europepmc   +1 more source

Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab. [PDF]

Biologics
Otake H, Matsumoto S, Mashima H.
europepmc   +1 more source

Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study. [PDF]

Cureus
Bland K, Jubber A, Ganguly S, Moorthy A.
europepmc   +1 more source

Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review. [PDF]

Acta Oncol
Ekedahl H, Sigurjonsdottir G, Bergqvist V, Båtshake B, Carneiro A, Marsal J.   +5 more
europepmc   +1 more source

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry. [PDF]

RMD Open
Sonomoto K, Nakayamada S, Sakai H, Ueno M, Tanaka H, Nagayasu A, Aritomi T, Okawara M, Nakata A, Tanaka Y.   +9 more
europepmc   +1 more source